Bliss GVS Pharma Second Quarter 2025 Earnings: EPS: ₹2.31 (vs ₹4.06 in 2Q 2024)

Bliss GVS Pharma (NSE:BLISSGVS) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₹2.23b (up 5.1% from 2Q 2024).
• Net income: ₹242.6m (down 43% from 2Q 2024).
• Profit margin: 11% (down from 20% in 2Q 2024).
• EPS: ₹2.31 (down from ₹4.06 in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bliss GVS Pharma shares are down 22% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Bliss GVS Pharma (1 shouldn't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.